Development
Taysha Gene Therapies, Inc.
TSHA
$2.84
-$0.04-1.39%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -341.39% | 27.85% | 64.98% | -10.59% | 48.18% |
| Total Depreciation and Amortization | 19.49% | 25.64% | 27.31% | 74.16% | 66.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,988.47% | 34.53% | -70.30% | 433.74% | -22.88% |
| Change in Net Operating Assets | 3.57% | 81.07% | -345.43% | 1,257.75% | -161.17% |
| Cash from Operations | 37.70% | 43.73% | 50.69% | 135.46% | 9.78% |
| Capital Expenditure | 100.00% | 100.61% | 53.72% | 72.08% | 42.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -249.00% | -- | -- | 75.60% | -100.00% |
| Cash from Investing | -15.56% | 100.59% | 65.87% | 72.18% | 24.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -95.72% | -81.95% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -177.14% | 79.80% | -9.38% | 107.21% | -- |
| Cash from Financing | 136,637.86% | -96.60% | -245.79% | 357.63% | -100.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 473.27% | 39.65% | 53.40% | 235.04% | -436.06% |